The Role of Atropine in Preventing Myopia Progression: An Update

Chierigo, Alberto; Desideri, Lorenzo Ferro; Traverso, Carlo Enrico; Vagge, Aldo

doi:10.3390/pharmaceutics14050900

Cited by 25 publications

(18 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination treatments showed less rebound effect, signi cant with the dual focus lenses. Studies have shown that the rebound effect can be in uenced using different doses of atropine and method of washout [25]. A study has shown that after a year of dual-focus contact lens monotherapy, there was little to no rebound effect [26].…”

Section: Rebound Effectmentioning

confidence: 99%

WITHDRAWN: Combination Low-Concentration Atropine and Contact Lenses for Myopia Control

Erdinest

Atar-Vardi²,

Lavy

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose: To ascertain the effectivity of 0.01% atropine (A0.01%) treatment to inhibit myopia progression and the possible additive potency with peripheral defocus contact lenses over three years and the rebound effect one year after cessation of treatment. Methods: This prospective study included 127 children aged 8–15 years, divided into three treatment groups: A0.01% and single vision (SV) spectacles (At, n=36), A0.01% and peripheral defocus contact lens (At+PDCL, n=30), 0.01%At and dual focus (At+DF, n=25) and a control group prescribed SV spectacles (n=36). Cycloplegic spherical equivalence refraction (SER) was measured every six months during three years of treatment and one year after cessation. Results: Myopia progression decreased over three years of treatment, more during the second and third years than the first, to a statistically significant degree in the A0.01% monotherapy group(P<0.01): In the first, second, and third years respectively in the At group -0.42±0.34D, -0.19±0.18, -0.22±0.19D, in the At+PDCL group -0.26±0.21D, -0.14±0.37D and -0.15±0.31D, in the At+DF group -0.22±0.15D, -0.15±0.22D, and -0.11±0.14D. Myopia progressed one year after cessation of treatment: -0.29±0.28D in the At group, -0.13±0.28D in the At+PDCL group, and -0.09±0.18D in the At+DF group. After three years, there was no statistically significant difference in myopia progression between groups At and At+PDCL or At+DF (P<0.05). Conclusions: Low-dose atropine has been substantiated in this cohort as an effective treatment to decelerate myopia progression over three years, more effective in the second and third years of treatment. The combination treatment did not exhibit a statistically significant advantage over monotherapy in this cohort. The dual-focus lens group exhibited a statistically lower rebound effect than the monotherapy group.

show abstract

Section: Rebound Effectmentioning

confidence: 99%

WITHDRAWN: Combination Low-Concentration Atropine and Contact Lenses for Myopia Control

Erdinest

Atar-Vardi²,

Lavy

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…1% and 0.5%. 11 The outcome of this study is comparable to that conducted by Matteo Sacchi et al, in the European population. This study demonstrated that in the Atropine-treated group, the mean myopic progression was -0.54(0.61) D after 12 months.…”

Section: Discussionsupporting

confidence: 88%

Atropine 0.01% Eye Drops for Myopia Control in a tertiary care center of Pakistan: An interventional case series

Saleem,

Syeda Aisha Bokhari

2024

pak J Ophthalmol

View full text Add to dashboard Cite

Purpose: To evaluate the real time results of once-dailyAtropine 0.01% eye drops in controlling myopia. Study Design: Interventional case series. Place and Duration of Study: The Eye Centre, South City Hospital, Karachi from September 2020 to August 2021. Methods: One hundred(both) eyes of 50 children were included in the study using non-probability consecutive sampling technique. Baseline spherical equivalent refraction(SER) was recorded at the initiation of treatment.The endpoint was measuring the rate of progression in SER at one year after treatment. Responders weredefined as the ones with either no progression of myopia or worsening of myopia of ≤ -0.50 SER and non-responders were defined as ones with a progression rate of myopia of greater than0.50 SER. Results: The baseline means SER for 100 eyes was 3.25±1.37 D. On follow-up after 12 months of treatment with Atropine 0.01% eye drops, the mean SER was -3.74 ± 1.34 D. The rate of SER progression was significantly lower at one year follow-up (p-value<0.001). The percentage of responders was84%. Conclusion: Significant reduction in myopia progression occurred after treatment with Atropine 0.01% eye drops in a greater percentage of children. This has led us to be confident in providing Atropine 0.01% eye drops along with simple spectacles as an effective treatment strategy to control myopia progression.

show abstract

“…Myopia is characterized by blurred vision of distant objects, which can be due to the increase in the axial length of the eye that causes the light to focus in front of the retina instead of on the retina [22]. Despite lenses and laser surgery are being largely used in the management of myopia, atropine seems to be a very effective pharmacological therapy, at least for children [23]. In fact, it is largely used in Asia, while it is less diffused in Europe because of possible side effects such as photophobia and poor visual acuity [24].…”

Section: Exploitation Of Plant Alkaloids In Ophthalmologymentioning

confidence: 99%

Eye Diseases: When the Solution Comes from Plant Alkaloids

Lorrai,

Cavaterra,

Giammaria

et al. 2024

Planta Med

View full text Add to dashboard Cite

Plants are an incredible source of metabolites showing a wide range of biological activities. Among these, there are the alkaloids, which have been exploited for medical purposes since ancient times. Nowadays, many plant-derived alkaloids are the main component of drugs used as therapy for different human diseases. This review deals with providing an overview of the alkaloids used to treat eye diseases describing the historical outline, the plants from which they are extracted and the clinical and molecular data supporting their therapeutic activity. Among the different alkaloids that have found application in medicine so far, atropine and pilocarpine are the most characterized ones. Conversely, caffeine and berberine have been proposed for the treatment of different eye disorders, but further studies still are necessary to fully understand their clinical value. Lastly, the alkaloid used for managing hypertension, reserpine, has been recently identified as a potential drug for ameliorating retinal disorders. Other important aspects discussed in this review are different solutions for alkaloid production. Given that the industrial production of many of the plant-derived alkaloids still relies on extraction from plants and the chemical synthesis can be highly expensive and poorly efficient, alternative methods need to be found. Biotechnologies offer a multitude of possibilities to overcome these issues, spanning from genetic engineering, synthetic biology for microorganisms and bioreactors for plant cell cultures. However, further efforts are needed to completely satisfy the pharmaceutical demand.

show abstract

The Role of Atropine in Preventing Myopia Progression: An Update

Cited by 25 publications

References 94 publications

WITHDRAWN: Combination Low-Concentration Atropine and Contact Lenses for Myopia Control

WITHDRAWN: Combination Low-Concentration Atropine and Contact Lenses for Myopia Control

Atropine 0.01% Eye Drops for Myopia Control in a tertiary care center of Pakistan: An interventional case series

Eye Diseases: When the Solution Comes from Plant Alkaloids

Contact Info

Product

Resources

About